X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals (Nasdaq:XFOR) granted stock options as inducement awards to new employees under its 2019 Inducement Equity Incentive Plan, effective July 6, 2026.

Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq:XFOR) granted stock options as inducement awards to new employees under its 2019 Inducement Equity Incentive Plan, effective July 6, 2026.

The awards cover 750,000 shares at a $4.03 exercise price, with a ten-year term and four-year vesting schedule.

Positive

• Inducement grants cover options for 750,000 common shares
• Exercise price of $4.03 matches July 6, 2026 closing share price
• Four-year vesting schedule supports long-term employee retention
• Options approved by the board’s Compensation Committee under Nasdaq Rule 5635(c)(4)

Negative

• Issuance of 750,000 options may create future shareholder dilution
• Vesting contingent on continued employment may lead to unvested forfeitures

Argus Jul 8 session 1 alert

+0.51% close to close 0.2x rel. volume Open Argus

Details

News Market Reaction – XFOR

$389.54M Mkt Cap at Peak Alert

On Jul 8, the first trading day after this news, XFOR closed 0.51% above the previous close.

Data tracked by StockTitan Argus for the Jul 8 session.

Key Figures

Inducement options granted: 750,000 shares Option term: 10 years Exercise price: $4.03 per share +3 more

Inducement options granted

750,000 shares

Aggregate options to purchase common stock for new employees

Option term

10 years

Ten-year term for inducement stock options

Exercise price

$4.03 per share

Equal to X4’s July 6, 2026 closing price

Vesting period

4 years

Options vest over four years subject to continued employment

Initial vesting tranche

25% after 12 months

First portion of options vests one year after grant date

Remaining vesting schedule

36 months monthly

Balance vests monthly over the following 36 months

Historical Context

5 past events · Latest: Jul 01

5 events

1. Jul 01

   board appointment

   24h Move

   -12.5%

   Appointment of experienced CFO Kelly Gold to the Board and Audit Committee.

2. Jun 01

   inducement grants

   24h Move

   -1.7%

   Inducement stock options for new employees under the 2019 Inducement Plan.

3. May 27

   conference appearance

   24h Move

   +0.8%

   Planned presentation at the 2026 Jefferies Global Healthcare Conference.

4. May 06

   1Q26 earnings

   24h Move

   +4.3%

   Q1 2026 results, EU approval of XOLREMDI and cash runway disclosure.

5. Apr 29

   EU drug approval

   24h Move

   -0.5%

   European Commission authorization of XOLREMDI for WHIM syndrome patients.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), inducement awards, equity awards, exercise price

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement awards financial

"the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan"

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

equity awards financial

"The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals"

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

exercise price financial

"The options have a ten-year term and an exercise price of $4.03 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 6, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 750,000 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.

The options have a ten-year term and an exercise price of $4.03 per share, which is equal to the closing price of X4’s common stock on July 6, 2026. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee’s continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

About X4 Pharmaceuticals

X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is approved in the U.S. and EU as XOLREMDI^® for patients with WHIM syndrome. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

X4 Investor Contact:
Remy Bernarda
Jenny Kobin
IR Advisory Solutions
ir@x4pharma.com

Source: X4 Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement grants did X4 Pharmaceuticals (XFOR) announce on July 7, 2026?

X4 Pharmaceuticals announced stock option inducement awards for new employees covering 750,000 shares of common stock. According to X4 Pharmaceuticals, these options were granted under its 2019 Inducement Equity Incentive Plan as material inducements to join the company.

What is the exercise price of the new X4 Pharmaceuticals (XFOR) inducement stock options?

The inducement stock options have an exercise price of $4.03 per share. According to X4 Pharmaceuticals, this price equals the closing price of its common stock on July 6, 2026, the effective grant date.

How long is the term of the X4 Pharmaceuticals (XFOR) inducement stock options granted in July 2026?

The inducement stock options have a ten-year term from the grant date. According to X4 Pharmaceuticals, this long duration gives new employees extended time to exercise their options if vesting and other conditions are satisfied.

What is the vesting schedule for the July 2026 X4 Pharmaceuticals (XFOR) inducement option grants?

The options vest over four years, with 25% vesting after 12 months and the rest monthly over 36 months. According to X4 Pharmaceuticals, vesting requires the employee to remain employed on each vesting date.

Under which plan were the July 2026 X4 Pharmaceuticals (XFOR) inducement options granted?

The options were granted under the 2019 Inducement Equity Incentive Plan. According to X4 Pharmaceuticals, this plan is used exclusively for equity awards to individuals who were not previously employees of the company.

How do the X4 Pharmaceuticals (XFOR) inducement grants relate to Nasdaq Listing Rule 5635(c)(4)?

The stock options were granted as inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4). According to X4 Pharmaceuticals, these grants were approved by the Compensation Committee as material incentives for new hires.